Drug intelligence / Profile preview

h 103

Development stage: Unknown
Lead developer: Shanghai Sunway Biotech
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intratumoral, Intravenous

Overview

H 103 is a recombinant oncolytic adenovirus injection being developed by Shanghai Sunway Biotech for the treatment of cancer. It functions as a p53 gene modulator, which is likely intended to restore or enhance p53 tumor suppressor activity in cancer cells.

Brand names: Oncolytic recombinant adenovirus injection

Targets

TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on h 103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on h 103.

Explore the full profile